Submit Manuscript  

Article Details


Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer’s Treatment

Author(s):

Bijo Mathew*   Pages 1 - 5 ( 5 )

Abstract:


Background: Multi-functional design of ligands emerged as new drug design paradigm of Alzheimer’s disease (AD). Given the complexity of AD, the molecules showing dual inhibition of monoamine oxidase (MAO) and acetylcho- linesterase (AChE) with neuroprotective properties could prevent the progressive neural degeneration effectively.

Materials and methods: Numerous studies documented that chalcone is a privileged structural framework for the inhibition of both MAO and AChE.

Results: The recent studies suggested that the development of chalcone candidates endowed with pharmacophores of FDA approved drugs may become an active molecules in the field of current AD research.

Conclusion: The current perspective described the recent updates of chalcone moiety linked with the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors for the prophylactic agents for AD.

Keywords:

Chalcones, pharmacophore, monoamine oxidase, acetylcholinesterase, flurbiprofen, rivastigmine.

Affiliation:

Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad, 678557, Kerala



Read Full-Text article